MESTINON 60 Milligram Tablets

Pays: Irlande

Langue: anglais

Source: HPRA (Health Products Regulatory Authority)

Ingrédients actifs:

PYRIDOSTIGMINE BROMIDE

Disponible depuis:

Meda Health Sales Ireland Limited

Code ATC:

N07AA02

DCI (Dénomination commune internationale):

PYRIDOSTIGMINE BROMIDE

Dosage:

60 Milligram

forme pharmaceutique:

Tablets

Type d'ordonnance:

Product subject to prescription which may be renewed (B)

Domaine thérapeutique:

Anticholinesterases

Statut de autorisation:

Authorised

Date de l'autorisation:

2011-06-10

Notice patient

PACKAGE LEAFLET: 
INFORMATION FOR THE USER 
MESTINON 
60 MG TABLETS  
Pyridostigmine bromide 

READ ALL OF
THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT 
INFORMATION FOR YOU. 
- 
Keep this leaflet. You may need to read it again. 
- 
If you have any further
questions, ask your doctor or pharmacist. 
- 
This medicine has been prescribed for you only. Do not pass
it on to others. It may harm 
them, even if their signs of illness are the
same as yours.  
- 
If you get any side effects, talk to your doctor or
pharmacist. This includes any side effects 
not listed in this leaflet. 

WHAT IS IN THIS LEAFLET: 
1.  What Mestinon tablets are and what they are used for 
2.  What you need to know before you take Mestinon tablets 
3.  How to take Mestinon tablets 
4.  Possible side effects 
5.  How to store Mestinon tablets 
6.  Contents of the pack and other information 

1.  WHAT MESTINON TABLETS ARE AND WHAT THEY ARE USED FOR 
Mestinon tablets contain the active ingredient
pyridostigmine, which belongs to a group of 
medicines
called anticholinesterases, which improve the communication between the nerves and 
the muscles. 
Mestinon tablets are used for: 


Treatment of myasthenia gravis – a disease of the
immune system causing muscle weakness 


Paralytic ileus – a condition where the digestive tract does not work
because its muscles are 
paralysed 


Urinary retention after surgery – failure to urinate cause by an anaesthetic or
certain types 
or surgery. 
2.  WHAT YOU NEED TO KNOW BEFORE YOU TAKE MESTINON TABLETS 
DO NOT TAKE MESTINON TABLETS: 
- 
If your digestive tract is
twisted or blocked by an obstruction. 
- 
If you cannot pass urine because of an obstruction. 
- 
If you are allergic to pyrido

Résumé des caractéristiques du produit

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Mestinon 60mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each Tablet contains 60.0mg pyridostigmine bromide.
Each Tablet contains 60.75mg lactose monohydrate.
_For excipients, see section 6.1._
3 PHARMACEUTICAL FORM
Tablet
White to off-white, round, biplanar, bevel-edged tablets imprinted
with “V” M60 across one face and with two break
marks forming a cross on the other.
The tablet can be divided into equal halves.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Myasthenia gravis, paralytic ileus and post-operative urinary
retention.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
_Myasthenia gravis_
_Adults_
Doses of 30 to 120mg are given at intervals throughout the day when
maximum strength is needed (for example, on
rising and before mealtimes). The usual duration of action of a dose
is 3 to 4 hours in the daytime but a longer effect (6
hours) is often obtained with a dose taken on retiring for bed.
The total daily dose is usually in the range of 5 - 20 tablets but
doses higher than these may be needed by some
patients.
_Children_
Children under 6 years old should receive an initial dose of half a
tablet (30mg) of Mestinon; children 6-12 years old
should receive one tablet (60mg). Dosage should be increased
gradually, in increments of 15-30mg daily, until
maximum improvement is obtained. Total daily requirements are usually
in the range of 30 - 360mg
_Other Indications (paralytic ileus)_
_Adults_
The usual dose is 1 to 4 tablets (60 to 240mg) per day.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___